# PMV Pharmaceuticals, Inc.: financial statements, quarterly

PMVP · Nasdaq · CIK 1699382 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pmvp.md) · [Financials](/companies/pmvp/financials.md) · [Filings](/companies/pmvp/filings.md) · [Insiders](/companies/pmvp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pmvp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [13.6](/filings/0000950170-24-122817.md) | [13.4 d](/filings/0001193125-26-095014.md) | [13.2](/filings/0000950170-25-067513.md) | [14.6](/filings/0000950170-25-104588.md) | [16.9](/filings/0001193125-25-276003.md) | [13.8 d](/filings/0001193125-26-095014.md) | [17.4](/filings/0001193125-26-218227.md) | [18.4](/filings/0001193125-26-350448.md) | [18.2](/filings/0001193125-25-276003.md) | [15.8 d](/filings/0001193125-26-095014.md) | [15.3](/filings/0001193125-26-218227.md) | [14.7](/filings/0001193125-26-350448.md) |
| Operating income | $m | [(19.6)](/filings/0000950170-24-122817.md) | [(18.9) d](/filings/0001193125-26-095014.md) | [(18.2)](/filings/0000950170-25-067513.md) | [(20.2)](/filings/0000950170-25-104588.md) | [(21.9)](/filings/0001193125-25-276003.md) | [(25.2) d](/filings/0001193125-26-095014.md) | [(21.6)](/filings/0001193125-26-218227.md) | [(22.9)](/filings/0001193125-26-350448.md) | [(22.5)](/filings/0001193125-25-276003.md) | [(19.2) d](/filings/0001193125-26-095014.md) | [(19.0)](/filings/0001193125-26-218227.md) | [(18.9)](/filings/0001193125-26-350448.md) |
| Income tax | $m | [(0.0) d](/filings/0000950170-24-122817.md) | [(0.0) d](/filings/0001193125-26-095014.md) | not reported | [(16.2)](/filings/0000950170-25-104588.md) | [0.1](/filings/0001193125-25-276003.md) | [0.0 d](/filings/0001193125-26-095014.md) | [(2.2)](/filings/0001193125-26-218227.md) | [0.0](/filings/0001193125-26-350448.md) | [(0.0)](/filings/0001193125-25-276003.md) | [0.0 d](/filings/0001193125-26-095014.md) | not reported | [0.0](/filings/0001193125-26-350448.md) |
| Net income | $m | [(16.6)](/filings/0000950170-24-122817.md) | [(15.8) d](/filings/0001193125-26-095014.md) | [(15.3)](/filings/0001193125-25-276003.md) | [(1.2)](/filings/0001193125-25-276003.md) | [(19.2)](/filings/0001193125-25-276003.md) | [(23.0) d](/filings/0001193125-26-095014.md) | [(17.4)](/filings/0001193125-26-350448.md) | [(21.2)](/filings/0001193125-26-350448.md) | [(21.1)](/filings/0001193125-25-276003.md) | [(18.0) d](/filings/0001193125-26-095014.md) | [(18.0)](/filings/0001193125-26-350448.md) | [(18.1)](/filings/0001193125-26-350448.md) |
| Diluted EPS | $ per share | [(0.34)](/filings/0000950170-24-122817.md) | not reported | [(0.30)](/filings/0000950170-25-067513.md) | [(0.02)](/filings/0000950170-25-104588.md) | [(0.37)](/filings/0001193125-25-276003.md) | not reported | [(0.34)](/filings/0001193125-26-218227.md) | [(0.41)](/filings/0001193125-26-350448.md) | [(0.40)](/filings/0001193125-25-276003.md) | not reported | [(0.34)](/filings/0001193125-26-218227.md) | [(0.34)](/filings/0001193125-26-350448.md) |
| Basic EPS | $ per share | [(0.34)](/filings/0000950170-24-122817.md) | not reported | [(0.30)](/filings/0000950170-25-067513.md) | [(0.02)](/filings/0000950170-25-104588.md) | [(0.37)](/filings/0001193125-25-276003.md) | not reported | [(0.34)](/filings/0001193125-26-218227.md) | [(0.41)](/filings/0001193125-26-350448.md) | [(0.40)](/filings/0001193125-25-276003.md) | not reported | [(0.34)](/filings/0001193125-26-218227.md) | [(0.34)](/filings/0001193125-26-350448.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [52.1](/filings/0000950170-23-061551.md) | [37.7](/filings/0000950170-25-030414.md) | [47.7](/filings/0000950170-24-056295.md) | [48.5](/filings/0000950170-24-093343.md) | [48.8](/filings/0000950170-24-122817.md) | [40.9](/filings/0001193125-26-095014.md) | [51.3](/filings/0000950170-25-067513.md) | [44.1](/filings/0000950170-25-104588.md) | [36.3](/filings/0001193125-25-276003.md) | [38.0](/filings/0001193125-26-350448.md) | [39.1](/filings/0001193125-26-218227.md) | [12.5](/filings/0001193125-26-350448.md) |
| Current assets | $m | [205](/filings/0000950170-23-061551.md) | [207](/filings/0000950170-25-030414.md) | [202](/filings/0000950170-24-056295.md) | [219](/filings/0000950170-24-093343.md) | [190](/filings/0000950170-24-122817.md) | [176](/filings/0001193125-26-095014.md) | [163](/filings/0000950170-25-067513.md) | [145](/filings/0000950170-25-104588.md) | [132](/filings/0001193125-25-276003.md) | [115](/filings/0001193125-26-350448.md) | [95.8](/filings/0001193125-26-218227.md) | [81.4](/filings/0001193125-26-350448.md) |
| Total assets | $m | [261](/filings/0000950170-23-061551.md) | [252](/filings/0000950170-25-030414.md) | [237](/filings/0000950170-24-056295.md) | [238](/filings/0000950170-24-093343.md) | [223](/filings/0000950170-24-122817.md) | [191](/filings/0001193125-26-095014.md) | [171](/filings/0000950170-25-067513.md) | [153](/filings/0000950170-25-104588.md) | [134](/filings/0001193125-25-276003.md) | [117](/filings/0001193125-26-350448.md) | [96.6](/filings/0001193125-26-218227.md) | [82.1](/filings/0001193125-26-350448.md) |
| Current liabilities | $m | [10.7](/filings/0000950170-23-061551.md) | [14.0](/filings/0000950170-25-030414.md) | [12.1](/filings/0000950170-24-056295.md) | [11.4](/filings/0000950170-24-093343.md) | [13.6](/filings/0000950170-24-122817.md) | [14.4](/filings/0001193125-26-095014.md) | [9.8](/filings/0000950170-25-067513.md) | [11.6](/filings/0000950170-25-104588.md) | [12.3](/filings/0001193125-25-276003.md) | [11.4](/filings/0001193125-26-350448.md) | [8.6](/filings/0001193125-26-218227.md) | [10.6](/filings/0001193125-26-350448.md) |
| Total liabilities | $m | [23.4](/filings/0000950170-23-061551.md) | [26.5](/filings/0000950170-25-030414.md) | [24.2](/filings/0000950170-24-056295.md) | [23.2](/filings/0000950170-24-093343.md) | [25.6](/filings/0000950170-24-122817.md) | [15.2](/filings/0001193125-26-095014.md) | [10.5](/filings/0000950170-25-067513.md) | [12.3](/filings/0000950170-25-104588.md) | [12.8](/filings/0001193125-25-276003.md) | [11.9](/filings/0001193125-26-350448.md) | [8.6](/filings/0001193125-26-218227.md) | [10.6](/filings/0001193125-26-350448.md) |
| Shareholders' equity | $m | [238](/filings/0000950170-24-122817.md) | [226](/filings/0001193125-26-095014.md) | [213](/filings/0001193125-25-276003.md) | [214](/filings/0001193125-25-276003.md) | [198](/filings/0001193125-25-276003.md) | [176](/filings/0001193125-26-350448.md) | [160](/filings/0001193125-26-350448.md) | [141](/filings/0001193125-26-350448.md) | [121](/filings/0001193125-25-276003.md) | [105](/filings/0001193125-26-350448.md) | [88.0](/filings/0001193125-26-350448.md) | [71.5](/filings/0001193125-26-350448.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.7) d](/filings/0000950170-24-122817.md) | [(12.1) d](/filings/0001193125-26-095014.md) | [(16.2)](/filings/0000950170-25-067513.md) | [(1.6) d](/filings/0000950170-25-104588.md) | [(16.8) d](/filings/0001193125-25-276003.md) | [(16.7) d](/filings/0001193125-26-095014.md) | [(18.3)](/filings/0001193125-26-218227.md) | [(18.3) d](/filings/0001193125-26-350448.md) | [(19.8) d](/filings/0001193125-25-276003.md) | [(17.2) d](/filings/0001193125-26-095014.md) | [(19.7)](/filings/0001193125-26-218227.md) | [(14.6) d](/filings/0001193125-26-350448.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-122817.md) | [0.2 d](/filings/0001193125-26-095014.md) | [0.6](/filings/0000950170-25-067513.md) | [0.0 d](/filings/0000950170-25-104588.md) | [0.0 d](/filings/0001193125-25-276003.md) | [0.1 d](/filings/0001193125-26-095014.md) | [0.0](/filings/0001193125-26-218227.md) | [0.0 d](/filings/0001193125-26-350448.md) | [(0.0) d](/filings/0001193125-25-276003.md) | [0.0 d](/filings/0001193125-26-095014.md) | [0.0](/filings/0001193125-26-218227.md) | [0.0 d](/filings/0001193125-26-350448.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q3 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [45.6](/filings/0000950170-23-061551.md) | [45.8](/filings/0000950170-24-056295.md) | [45.8](/filings/0000950170-24-093343.md) | [49.0](/filings/0000950170-24-122817.md) | [51.4](/filings/0000950170-25-067513.md) | [51.5](/filings/0000950170-25-104588.md) | [51.6](/filings/0001193125-25-276003.md) | [52.0](/filings/0001193125-26-218227.md) | [52.0](/filings/0001193125-26-350448.md) | [53.0](/filings/0001193125-25-276003.md) | [53.3](/filings/0001193125-26-218227.md) | [53.4](/filings/0001193125-26-350448.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 53,458,058 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-350448.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.